Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes.

Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier PJ, Satake E, Simeone CA, Shah H, Qiu C, Looker HC, Fiorina P, Ware CF, Sun JK, Doria A, Kretzler M, Susztak K, Duffin KL, Nelson RG, Krolewski AS.

Nat Med. 2019 May;25(5):805-813. doi: 10.1038/s41591-019-0415-5. Epub 2019 Apr 22.

PMID:
31011203
2.

Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy.

Skupien J, Smiles AM, Valo E, Ahluwalia TS, Gyorgy B, Sandholm N, Croall S, Lajer M, McDonnell K, Forsblom C, Harjutsalo V, Marre M, Galecki AT, Tregouet DA, Wu CY, Mychaleckyj JC, Nickerson H, Pragnell M, Rich SS, Pezzolesi MG, Hadjadj S, Rossing P, Groop PH, Krolewski AS.

Diabetes Care. 2019 Jan;42(1):93-101. doi: 10.2337/dc18-1369. Epub 2018 Nov 19.

PMID:
30455333
3.

A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes.

van Zuydam NR, Ahlqvist E, Sandholm N, Deshmukh H, Rayner NW, Abdalla M, Ladenvall C, Ziemek D, Fauman E, Robertson NR, McKeigue PM, Valo E, Forsblom C, Harjutsalo V; Finnish Diabetic Nephropathy Study (FinnDiane), Perna A, Rurali E, Marcovecchio ML, Igo RP Jr, Salem RM, Perico N, Lajer M, Käräjämäki A, Imamura M, Kubo M, Takahashi A, Sim X, Liu J, van Dam RM, Jiang G, Tam CHT, Luk AOY, Lee HM, Lim CKP, Szeto CC, So WY, Chan JCN; Hong Kong Diabetes Registry Theme-based Research Scheme Project Group, Ang SF, Dorajoo R, Wang L, Clara TSH, McKnight AJ, Duffy S; Warren 3 and Genetics of Kidneys in Diabetes (GoKinD) Study Group, Pezzolesi MG; GENIE (GEnetics of Nephropathy an International Effort) Consortium, Marre M, Gyorgy B, Hadjadj S, Hiraki LT; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group, Ahluwalia TS, Almgren P, Schulz CA, Orho-Melander M, Linneberg A, Christensen C, Witte DR, Grarup N, Brandslund I, Melander O, Paterson AD, Tregouet D, Maxwell AP, Lim SC, Ma RCW, Tai ES, Maeda S, Lyssenko V, Tuomi T, Krolewski AS, Rich SS, Hirschhorn JN, Florez JC, Dunger D, Pedersen O, Hansen T, Rossing P, Remuzzi G; SUrrogate markers for Micro- and Macrovascular hard endpoints for Innovative diabetes Tools (SUMMIT) Consortium, Brosnan MJ, Palmer CNA, Groop PH, Colhoun HM, Groop LC, McCarthy MI.

Diabetes. 2018 Jul;67(7):1414-1427. doi: 10.2337/db17-0914. Epub 2018 Apr 27.

4.

Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes.

Satake E, Pezzolesi MG, Md Dom ZI, Smiles AM, Niewczas MA, Krolewski AS.

Diabetes. 2018 May;67(5):1013-1023. doi: 10.2337/db17-1207. Epub 2018 Feb 16.

5.

Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, Galecki AT, Duffin KL, Breyer MD, Pullen N, Bonventre JV, Krolewski AS.

Kidney Int. 2018 May;93(5):1198-1206. doi: 10.1016/j.kint.2017.11.024. Epub 2018 Feb 2.

6.
7.

Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.

Yamanouchi M, Skupien J, Niewczas MA, Smiles AM, Doria A, Stanton RC, Galecki AT, Duffin KL, Pullen N, Breyer MD, Bonventre JV, Warram JH, Krolewski AS.

Kidney Int. 2017 Jul;92(1):258-266. doi: 10.1016/j.kint.2017.02.010. Epub 2017 Apr 7.

8.

Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes.

Krolewski AS, Skupien J, Rossing P, Warram JH.

Kidney Int. 2017 Jun;91(6):1300-1311. doi: 10.1016/j.kint.2016.10.046. Epub 2017 Mar 31. Review.

9.

Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease.

Niewczas MA, Mathew AV, Croall S, Byun J, Major M, Sabisetti VS, Smiles A, Bonventre JV, Pennathur S, Krolewski AS.

Diabetes Care. 2017 Mar;40(3):383-390. doi: 10.2337/dc16-0173. Epub 2017 Jan 13.

10.

Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes.

Skupien J, Warram JH, Smiles AM, Stanton RC, Krolewski AS.

Diabetes Care. 2016 Dec;39(12):2262-2269. Epub 2016 Sep 19.

11.

Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes.

Nowak N, Skupien J, Niewczas MA, Yamanouchi M, Major M, Croall S, Smiles A, Warram JH, Bonventre JV, Krolewski AS.

Kidney Int. 2016 Feb;89(2):459-67.

12.

Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes.

Pavkov ME, Weil EJ, Fufaa GD, Nelson RG, Lemley KV, Knowler WC, Niewczas MA, Krolewski AS.

Kidney Int. 2016 Jan;89(1):226-34. doi: 10.1038/ki.2015.278. Epub 2016 Jan 4.

13.

Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes.

Orlov S, Cherney DZ, Pop-Busui R, Lovblom LE, Ficociello LH, Smiles AM, Warram JH, Krolewski AS, Perkins BA.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1136-44. doi: 10.2215/CJN.11441114. Epub 2015 Jun 19.

14.

Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes.

Krolewski AS.

Diabetes Care. 2015 Jun;38(6):954-62. doi: 10.2337/dc15-0184. Review.

15.

Circulating TGF-β1-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes.

Pezzolesi MG, Satake E, McDonnell KP, Major M, Smiles AM, Krolewski AS.

Diabetes. 2015 Sep;64(9):3285-93. doi: 10.2337/db15-0116. Epub 2015 Apr 30.

16.

Differential Gene Expression in Diabetic Nephropathy in Individuals With Type 1 Diabetes.

Caramori ML, Kim Y, Goldfine AB, Moore JH, Rich SS, Mychaleckyj JC, Kirkpatrick D, Nickerson H, Krolewski AS, Mauer M.

J Clin Endocrinol Metab. 2015 Jun;100(6):E876-82. doi: 10.1210/jc.2014-4465. Epub 2015 Apr 14.

PMID:
25871838
17.

Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes.

Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, Niewczas MA.

Kidney Int. 2015 Apr;87(4):812-9. doi: 10.1038/ki.2014.330. Epub 2014 Oct 1.

18.

Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria.

Skupien J, Warram JH, Smiles A, Galecki A, Stanton RC, Krolewski AS.

J Am Soc Nephrol. 2014 Dec;25(12):2916-25. doi: 10.1681/ASN.2013091002. Epub 2014 Jun 5.

19.

Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes.

Sabbisetti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A, Ito K, Sharma S, Ramadesikan S, Lee M, Briskin R, De Jager PL, Ngo TT, Radlinski M, Dear JW, Park KB, Betensky R, Krolewski AS, Bonventre JV.

J Am Soc Nephrol. 2014 Oct;25(10):2177-86. doi: 10.1681/ASN.2013070758. Epub 2014 Jun 5.

20.

Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria.

Skupien J, Warram JH, Niewczas MA, Gohda T, Malecki M, Mychaleckyj JC, Galecki AT, Krolewski AS.

Diabetes Care. 2014 Sep;37(9):2601-8. doi: 10.2337/dc13-1983. Epub 2014 Jun 4.

21.

Role of podocyte B7-1 in diabetic nephropathy.

Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, D'Addio F, Chin M, Tezza S, Ben Nasr M, Mattinzoli D, Ikehata M, Corradi D, Schumacher V, Buvall L, Yu CC, Chang JM, La Rosa S, Finzi G, Solini A, Vincenti F, Rastaldi MP, Reiser J, Krolewski AS, Mundel PH, Sayegh MH.

J Am Soc Nephrol. 2014 Jul;25(7):1415-29. doi: 10.1681/ASN.2013050518. Epub 2014 Mar 27.

22.

Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.

Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, Smiles A, Huang X, Walker W, Byun J, Karoly ED, Kensicki EM, Berry GT, Bonventre JV, Pennathur S, Meyer TW, Krolewski AS.

Kidney Int. 2014 May;85(5):1214-24. doi: 10.1038/ki.2013.497. Epub 2014 Jan 15.

23.

Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.

Krolewski AS, Gohda T, Niewczas MA.

Clin Exp Nephrol. 2014 Aug;18(4):571-83. doi: 10.1007/s10157-013-0900-y. Epub 2013 Nov 12. Review.

24.

Diabetic nephropathy: is ESRD its only heritable phenotype?

Pezzolesi MG, Krolewski AS.

J Am Soc Nephrol. 2013 Oct;24(10):1505-7. doi: 10.1681/ASN.2013070769. Epub 2013 Sep 12. No abstract available.

25.

Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes.

Qi L, Qi Q, Prudente S, Mendonca C, Andreozzi F, di Pietro N, Sturma M, Novelli V, Mannino GC, Formoso G, Gervino EV, Hauser TH, Muehlschlegel JD, Niewczas MA, Krolewski AS, Biolo G, Pandolfi A, Rimm E, Sesti G, Trischitta V, Hu F, Doria A.

JAMA. 2013 Aug 28;310(8):821-8. doi: 10.1001/jama.2013.276305.

26.

Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria.

Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, Doria A, Warram JH.

Diabetes Care. 2014;37(1):226-34. doi: 10.2337/dc13-0985. Epub 2013 Aug 12.

27.

Cystatin-based estimated GFR versus creatinine-based and creatinine- and cystatin-based estimated GFR for ESRD and mortality risk in diabetes.

Skupien J, Warram JH, Groop PH, Krolewski AS.

Am J Kidney Dis. 2013 Jul;62(1):184-6. doi: 10.1053/j.ajkd.2013.03.029. Epub 2013 May 17. No abstract available.

PMID:
23684753
28.

Family-based association analysis confirms the role of the chromosome 9q21.32 locus in the susceptibility of diabetic nephropathy.

Pezzolesi MG, Jeong J, Smiles AM, Skupien J, Mychaleckyj JC, Rich SS, Warram JH, Krolewski AS.

PLoS One. 2013;8(3):e60301. doi: 10.1371/journal.pone.0060301. Epub 2013 Mar 29.

29.

Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1.

Lee JE, Gohda T, Walker WH, Skupien J, Smiles AM, Holak RR, Jeong J, McDonnell KP, Krolewski AS, Niewczas MA.

PLoS One. 2013;8(3):e58007. doi: 10.1371/journal.pone.0058007. Epub 2013 Mar 20.

30.

Transcriptome analysis of proximal tubular cells (HK-2) exposed to urines of type 1 diabetes patients at risk of early progressive renal function decline.

Wanic K, Krolewski B, Ju W, Placha G, Niewczas MA, Walker W, Warram JH, Kretzler M, Krolewski AS.

PLoS One. 2013;8(3):e57751. doi: 10.1371/journal.pone.0057751. Epub 2013 Mar 7.

31.

Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes.

Merchant ML, Niewczas MA, Ficociello LH, Lukenbill JA, Wilkey DW, Li M, Khundmiri SJ, Warram JH, Krolewski AS, Klein JB.

Kidney Int. 2013 Jun;83(6):1177-84. doi: 10.1038/ki.2013.8. Epub 2013 Mar 6.

32.

From single nucleotide polymorphism to transcriptional mechanism: a model for FRMD3 in diabetic nephropathy.

Martini S, Nair V, Patel SR, Eichinger F, Nelson RG, Weil EJ, Pezzolesi MG, Krolewski AS, Randolph A, Keller BJ, Werner T, Kretzler M.

Diabetes. 2013 Jul;62(7):2605-12. doi: 10.2337/db12-1416. Epub 2013 Feb 22.

33.

The genetic risk of kidney disease in type 2 diabetes.

Pezzolesi MG, Krolewski AS.

Med Clin North Am. 2013 Jan;97(1):91-107. doi: 10.1016/j.mcna.2012.10.005. Epub 2012 Dec 7. Review.

34.

High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline.

Krolewski AS, Bonventre JV.

Semin Nephrol. 2012 Sep;32(5):407-14. doi: 10.1016/j.semnephrol.2012.07.002.

35.

High risk of ESRD in type 1 diabetes: call for action: introduction.

Krolewski AS, Bonventre JV.

Semin Nephrol. 2012 Sep;32(5):405-6. doi: 10.1016/j.semnephrol.2012.07.001. No abstract available.

PMID:
23062979
36.

Serum concentration of cystatin C and risk of end-stage renal disease in diabetes.

Krolewski AS, Warram JH, Forsblom C, Smiles AM, Thorn L, Skupien J, Harjutsalo V, Stanton R, Eckfeldt JH, Inker LA, Groop PH.

Diabetes Care. 2012 Nov;35(11):2311-6. doi: 10.2337/dc11-2220. Epub 2012 Jul 30.

37.

The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease.

Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, Cantarovich D, Stanton R, Krolewski AS.

Kidney Int. 2012 Sep;82(5):589-97. doi: 10.1038/ki.2012.189. Epub 2012 May 23.

38.

Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes.

Perkins BA, Rabbani N, Weston A, Ficociello LH, Adaikalakoteswari A, Niewczas M, Warram J, Krolewski AS, Thornalley P.

PLoS One. 2012;7(4):e35655. doi: 10.1371/journal.pone.0035655. Epub 2012 Apr 25.

39.

Elevated urinary excretion of immunoglobulins in nonproteinuric patients with type 1 diabetes.

Gohda T, Walker WH, Wolkow P, Lee JE, Warram JH, Krolewski AS, Niewczas MA.

Am J Physiol Renal Physiol. 2012 Jul 1;303(1):F157-62. doi: 10.1152/ajprenal.00443.2011. Epub 2012 Apr 18.

40.

Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes.

Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X, Johnson AC, Crabtree G, Smiles AM, Mayadas TN, Warram JH, Krolewski AS.

J Am Soc Nephrol. 2012 Mar;23(3):516-24. doi: 10.1681/ASN.2011060628. Epub 2012 Jan 19.

41.

Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.

Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, Warram JH, Krolewski AS.

J Am Soc Nephrol. 2012 Mar;23(3):507-15. doi: 10.1681/ASN.2011060627. Epub 2012 Jan 19.

42.

Diabetes: Lowering serum uric acid levels to prevent kidney failure.

Doria A, Krolewski AS.

Nat Rev Nephrol. 2011 Aug 2;7(9):495-6. doi: 10.1038/nrneph.2011.107. No abstract available.

PMID:
21808278
43.

An intergenic region on chromosome 13q33.3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes.

Pezzolesi MG, Poznik GD, Skupien J, Smiles AM, Mychaleckyj JC, Rich SS, Warram JH, Krolewski AS.

Kidney Int. 2011 Jul;80(1):105-11. doi: 10.1038/ki.2011.64. Epub 2011 Mar 16.

44.

Risk for ESRD in type 1 diabetes remains high despite renoprotection.

Rosolowsky ET, Skupien J, Smiles AM, Niewczas M, Roshan B, Stanton R, Eckfeldt JH, Warram JH, Krolewski AS.

J Am Soc Nephrol. 2011 Mar;22(3):545-53. doi: 10.1681/ASN.2010040354. Epub 2011 Feb 25.

45.

Genetic variation in the matrix metalloproteinase genes and diabetic nephropathy in type 1 diabetes.

Kure M, Pezzolesi MG, Poznik GD, Katavetin P, Skupien J, Dunn JS, Mychaleckyj JC, Warram JH, Krolewski AS.

Mol Genet Metab. 2011 May;103(1):60-5. doi: 10.1016/j.ymgme.2011.01.001. Epub 2011 Jan 14.

46.

Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase.

Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH, Krolewski AS, Bonventre JV.

Kidney Int. 2011 Feb;79(4):464-70. doi: 10.1038/ki.2010.404. Epub 2010 Oct 27.

47.

Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.

Good DM, Zürbig P, Argilés A, Bauer HW, Behrens G, Coon JJ, Dakna M, Decramer S, Delles C, Dominiczak AF, Ehrich JH, Eitner F, Fliser D, Frommberger M, Ganser A, Girolami MA, Golovko I, Gwinner W, Haubitz M, Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M, Kliem V, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neusüss C, Novak J, Peter K, Rossing K, Rupprecht H, Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P.

Mol Cell Proteomics. 2010 Nov;9(11):2424-37. doi: 10.1074/mcp.M110.001917. Epub 2010 Jul 8.

48.

The pseudokinase tribbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse beta cells.

Liew CW, Bochenski J, Kawamori D, Hu J, Leech CA, Wanic K, Malecki M, Warram JH, Qi L, Krolewski AS, Kulkarni RN.

J Clin Invest. 2010 Aug;120(8):2876-88. doi: 10.1172/JCI36849. Epub 2010 Jul 1.

49.

Insights to the genetics of diabetic nephropathy through a genome-wide association study of the GoKinD collection.

Pezzolesi MG, Skupien J, Mychaleckyj JC, Warram JH, Krolewski AS.

Semin Nephrol. 2010 Mar;30(2):126-40. doi: 10.1016/j.semnephrol.2010.01.004. Review.

50.

High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.

Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS.

Diabetes Care. 2010 Jun;33(6):1337-43. doi: 10.2337/dc10-0227. Epub 2010 Mar 23.

Supplemental Content

Loading ...
Support Center